Sex Disparities in Hypoxic Vasodilation and Impact of Obesity
Launched by UNIVERSITY OF MISSOURI-COLUMBIA · Jan 21, 2022
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how men and women respond differently to low oxygen levels in the body, particularly in relation to obesity and the nervous system. Researchers want to understand the reasons behind these differences, which could help improve treatments for people with obesity. The trial is currently looking for participants aged 65 to 74 who have a body mass index (BMI) over 18. However, individuals with certain health issues, such as pregnancy, diagnosed sleep apnea, or significant heart or kidney problems, among others, are not eligible to participate.
If you qualify and decide to join the trial, you can expect to be part of important research that could shed light on how obesity affects blood flow and oxygen delivery in different sexes. This study aims to gather valuable information that could lead to better health outcomes for both men and women with obesity. Your participation could make a difference in understanding these important health issues!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • BMI \>18 kg/m2
- Exclusion Criteria:
- • Pregnancy, breastfeeding
- • Diagnosed sleep apnea or AHI \>10 events/hr
- • Current smoking/Nicotine use
- • Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy
- • Nerve/neurologic disease
- • Cardiovascular, hepatic, renal, respiratory disease
- • Blood pressure ≥140/90 mmHg
- • Diabetes, Polycystic ovarian syndrome
- • Communication barriers
- • Prescription medications, Sensitivity to lidocaine
About University Of Missouri Columbia
The University of Missouri-Columbia is a leading academic institution dedicated to advancing medical research and clinical innovation. As a prominent sponsor of clinical trials, the university leverages its extensive resources and expertise to facilitate groundbreaking studies aimed at improving patient outcomes across a variety of health conditions. With a commitment to ethical research practices and collaboration with multidisciplinary teams, the University of Missouri-Columbia strives to translate scientific discoveries into effective therapeutic interventions, ultimately enhancing the quality of care in the communities it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbia, Missouri, United States
Patients applied
Trial Officials
Jacqueline Limberg, Ph.D.
Principal Investigator
University of Missouri-Columbia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials